Inappropriate prescribing of compounded antiobesity formulas in Brazil

Pharmacoepidemiology and Drug Safety

Volumn 7, Issue 3, 1998, Pages 207-212

  Nappo, Solange A ^a,d   Melo De Oliveira, Evaldo ^b   Morosini, Simone ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Sociedade Bras Estudo S ^*  (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d Departamento de Psicobiologia EPMUnifesp   (Brazil)

Author keywords

Anorectic drugs; Antiobesity drugs; D,1 fenfluramine; D fenfluramine weight reducing drugs; Diethylpropion; Fenproporex; Magistral formulas; Medical prescription

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENZODIAZEPINE DERIVATIVE; DIURETIC AGENT; LAXATIVE; PLANT EXTRACT; THYROID HORMONE;

ARTICLE; BRAZIL; DRUG FORMULATION; DRUG SAFETY; HUMAN; OBESITY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 13144269655     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199805/06)7:3<207::AID-PDS335>3.0.CO;2-W     Document Type: Article

References (21)

1. WHO. Anorexígenes: No permitidos en produtos de asociacion (Italia). Noticias Farmaceuticas de la OMS, 9, Septembre, Geneva, World Health Organization, 1988.
2. King II, R. R. ISMA addresses problems associated with prescription drug misuse. Indiana Medicine 1988; 81: 151.
3. Instituto de Salud Publica de Chile. Farmacos anorexigenos. Boletin de Informaciones de Medicamentos 1992; 6: 33-38.
4. Instituto de Salud Publica de Chile. La peligrosa moda de las formulas antiobesidad. Boletin de Informaciones de Medicamentos 1992; 9: 13-15.
5. Nappo, S. A. and Carlini E. A. Países sulamericanos solicitam legislação proibindo fórmulas magistrais e associações medicamentosas para tratamento de obesidade. Boletin CEBRID 1993; 12: 4.
6. Institut Català de Farmacologia. Los riesgos de los tratamientos farmacológicos de la obesidad. Butletti Groc 1993; 86: 13-14.
7. Nappo, S. A. Consumption of anorexigenic amphetamine-like drugs (diethylpropion, fenproporex and mazindol) and of d,l-fenfluramine in Brazil during the years of 1988 and 1989. Pharmacoepidemiology and Drug Safety 1996; 5: 19-25.
8. INCB: International Narcotic Control Board. Psychotropic substances - Statistics for 1990. United Nations Publication E/INCB/1991/3, Vienna, 1991.
9. INCB: International Narcotic Control Board. Psychotropic substances - Statistics for 1991. United Nations Publication E/INCB/1992/3, Vienna, 1992.
10. INCB: International Narcotic Control Board. Psychotropic substances - Statistics for 1992. United Nations Publication E/INCB/1993/3, Vienna, 1993.
11. British National Formulary. Centrally acting appetite suppressants. British Medical Association and Royal Pharmaceutical Society of Great Britain, (Ed.) No. 25, London, 1993.
12. Levin, A. The non-medical misuse of fenfluramine by drug-dependent young South Africans. Post-graduate Medical Journal 1975; 51 (Suppl. 1): 186-188.
13. Douglas, J. G., Munro, J. F., Kitchin, A. H., Muir, A. L. and Proudfoot, A. T. Pulmonary hypertension and fenfluramine. British Medical Journal 1981; 283: 881-883.
14. Steel, J. M. and Briggs, M. Withdrawal depression in obese patients after fenfluramine treatment. British Medical Journal 1972; 3: 26-27.
15. Carney, M. W. P. Diethylpropion and psychosis. Clinical Neuropharmacology 1988; 11: 183-188.
16. Galloway, S. Mc. L., Farguhar, D. L. and Munro, J. F. The current status of antiobesity drugs. Postgraduate Medical Journal 1984; 60 (Suppl. 3): 19-26.
17. Khan, S. A., Spiegel, D. A. and Jobe, P. C. Psychotomimetic effects of anorectic drugs. American Family Physician 1987; 36: 107-112.
18. UNITED NATIONS. Amfepramone. In: Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted, or Not Approved by Governments. Department of International Economic and Social Affairs, United Nations, New York, 1991.
19. WHO Review Group. Use and abuse of benzodiazepines. Bulletin of the World Health Organization 1983; 61: 551-562.
20. Warneke, L. B. Benzodiazepines: abuse and new use. Canadian Journal of Psychiatry 1991; 36: 194-205.
21. Lader, M. H. and Petursson, H. Benzodiazepine derivatives - side effects and dangers. Biological Psychiatry 1981; 16: 1195-1201.